William Blair analyst Andrew Brackmann has reiterated their bullish stance on NEO stock, giving a Buy rating on April 25.
Andrew Brackmann has given his Buy rating due to a combination of factors including NeoGenomics’ strategic positioning and potential for growth. Despite mixed first-quarter results, the company’s core clinical business has shown resilience, meeting revenue expectations with a notable increase in volume. This suggests a strong foundation for future growth, especially as the management has raised revenue guidance for the year, reflecting confidence in key growth drivers such as new product launches and enhanced sales team productivity.
Additionally, the recent acquisition of Pathline is expected to contribute significantly to revenue in the coming years, further supporting the positive outlook. The stock is currently trading at levels considered undervalued, providing an opportunity for multiple expansions as the company continues to meet or exceed expectations. This undervaluation, combined with the strategic initiatives underway, forms the basis for the Buy rating, as the stock is poised for potential appreciation in value.
According to TipRanks, Brackmann is an analyst with an average return of -7.2% and a 33.33% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as NeoGenomics, Guardant Health, and Qiagen.